Tomasz Stryjewski

Tomasz "Tommy" Stryjewski, MD, serves as the Chief Scientific Officer, Director, and Co-Founder of Pykus Therapeutics since February 2016, focusing on biodegradable polymers for vitreoretinal surgery. Currently a vitreoretinal surgeon at Tallman Eye Associates, Stryjewski also works as a Clinical Consultant for Aldeyra Therapeutics in retinal diseases and previously held the position of Senior Medical Advisor at Hubble Therapeutics. Stryjewski co-founded Helio Vision, Inc., which developed treatments for rare vitreous and retina diseases before its acquisition by Aldeyra Therapeutics in 2019. Stryjewski's medical training includes a Doctor of Medicine (honors) from Harvard Medical School and a Master of Public Policy from Harvard Kennedy School, alongside an undergraduate degree in Biological Sciences from Louisiana State University.